The present invention relates to a composition comprising at least one inhibitor of the enzymatic complex conjugating ubiquitin Ubc13/Uev1a and at least one anti-hypertensive agent inhibiting the renin-angiotensin-aldosterone system and/or a hypoglycemic agent. Medical uses and pharmaceutical compositions comprising this composition also fall within the scope of the present invention. In particular, this composition can be used for the treatment or prevention of the renal fibrotic damage, in particular in patients suffering from diabetes.

The present invention relates to a composition comprising at least one inhibitor of the enzymatic complex conjugating ubiquitin Ubc13/Uev1a and at least one anti-hypertensive agent inhibiting the renin-angiotensin-aldosterone system and/or a hypoglycemic agent. Medical uses and pharmaceutical compositions comprising this composition also fall within the scope of the present invention. In particular, this composition can be used for the treatment or prevention of the renal fibrotic damage, in particular in patients suffering from diabetes.

The present invention provides 5-nitrofuran-2-amide derivatives and methods of using the same in the treatment of cancer and induction of apoptosis by activating C/EBP-homologous protein expression.

The present invention provides 5-nitrofuran-2-amide derivatives and methods of using the same in the treatment of cancer and induction of apoptosis by activating C/EBP-homologous protein expression.

This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of Friedreich's ataxia or other neurodegenerative disease, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of Friedreich's ataxia or other neurodegenerative disease.

This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of Friedreich's ataxia or other neurodegenerative disease, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of Friedreich's ataxia or other neurodegenerative disease.

The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.

The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.

The present invention relates to an application of a hydrazide compound in tumor treatment, and, in particular, the present invention provides a use of a compound represented by formula I, an optical isomer or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, being used for the preparation of a composition or formulation, said composition or formulation being used for the prevention and/or treatment of tumors. The compound of the present invention has significant and exceptional therapeutic effects on tumors having low or no expression of the NNMT gene, high expression of DNA methylase, high expression of UHRF1, high methylation level at the NNMT gene nucleotide site, and/or high methylation level at a DNA CpG site in the NNMT gene region.

##STR00001##

The present invention relates to an application of a hydrazide compound in tumor treatment, and, in particular, the present invention provides a use of a compound represented by formula I, an optical isomer or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, being used for the preparation of a composition or formulation, said composition or formulation being used for the prevention and/or treatment of tumors. The compound of the present invention has significant and exceptional therapeutic effects on tumors having low or no expression of the NNMT gene, high expression of DNA methylase, high expression of UHRF1, high methylation level at the NNMT gene nucleotide site, and/or high methylation level at a DNA CpG site in the NNMT gene region.

##STR00001##